Health Tech's AI Question Just Changed
CIOs Need New Vendor Diligence to Match
The question digital health investors ask about a startup has quietly shifted. It's no longer "who has AI?" It's "who has something AI alone can't provide?" That shift, according to Rock Health's H1 2026 funding report, should change how health system CIOs evaluate the vendors knocking on their door.
The money is back, as U.S. digital health startups raised $7.4 billion across 244 deals in the first half of 2026, up from $6.4 billion in the same period last year, with roughly the same deal count. The real story is where that money went: 20 mega deals of $100 million or more absorbed 45% of all capital, up from 22% just two years ago. Just 8% of deals now claim nearly half the funding.
For CIOs, that concentration is a signal worth reading carefully. Well-capitalized vendors aren't just building better point solutions anymore. They're racing to own more of the healthcare operating layer—expanding from a single use case into adjacent workflows, betting that more context across more tasks beats a narrow tool done well. Clinical documentation platforms are picking up diagnostic partnerships. Revenue cycle vendors are acquiring their way into adjacent RCM functions. The pattern shows up everywhere from ambient AI to imaging to care navigation.
That expansion creates a real problem for health systems already juggling dozens of point solutions: overlap. As vendors' roadmaps widen, CIOs may increasingly find themselves paying for redundant capability across two or three platforms that all quietly built the same feature. Vendor consolidation on the buyer's own roadmap—not just contract renewal—deserves a permanent line item in enterprise architecture reviews.
Four traits now separate durable vendors from disposable ones. As foundation models make basic AI capability commoditized, Rock Health's research points to four qualities investors are underwriting instead: founder teams with genuine clinical or operational backgrounds; platforms actively expanding to own more of the workflow; hands-on implementation support through forward-deployed engineers who embed with the customer rather than hand off a login; and network effects built through partnerships with health systems, medical societies, and data platforms that compound trust over time.
That third trait deserves CIO attention specifically. The forward-deployed engineer model—borrowed from Palantir and now standard at infrastructure vendors like Commure and Qualified Health, and increasingly at Anthropic and OpenAI's life sciences teams—signals a shift in what "implementation" is supposed to mean. Vendors betting on FDEs are implicitly admitting that off-the-shelf AI doesn't work out of the box in a real clinical environment. That's a useful admission. CIOs should ask any AI vendor directly: who's actually in the building three months after go-live, and what does that ongoing relationship cost?
The exit market is finally showing signs of life, which matters for vendor risk. Digital health hasn't logged an IPO this year, but Oura filed its S-1 in May and Whoop raised $575 million at a $10.1 billion valuation while eyeing its own public debut. Meanwhile, M&A activity is running hot—115 acquisitions in H1 —with revenue cycle management consolidating fastest, as IKS Health, Med-Metrix, and Innovaccer have all absorbed smaller competitors. Private equity is playing too: Thoreau Group's $12 billion deal for Ensemble Health was the half's largest.
None of that is abstract for a health system CIO. Every vendor evaluation should now include a frank assessment of acquisition risk—not just "will this company survive," but "will this company still be the company I signed with in eighteen months." A vendor riding a mega deal today could be an acquisition target, an acquirer itself, or a consolidation casualty by the time a multi-year contract is up for renewal.
Digital health's capital is flowing again, but it's flowing toward a narrower definition of what makes a technology partner worth betting on. AI got everyone into the room. What happens after that first contract is signed is what will determine who's still standing.